Ozmosi | ASN-001 Drug Profile
Drug Profile
Using advanced filters...

ASN-001

Alternative Names: ASN-001, ASN001, ASN 001
Clinical Status: Active
Latest Update: 2026-11-06
Latest Update Note: Clinical Trial Update

Product Description

(Sourced from: https://www.benzinga.com/pressreleases/26/11/g62949361/eton-pharmaceuticals-reports-third-quarter-2026-financial-results)

Mechanisms of Action: CYP17A1 Inhibitor

Novel Mechanism: No

Modality: Unknown

Route of Administration: N/A

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Company: Harrow Health
Company Location:
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 1: Prostate Cancer

Phase 0: Hemangioma

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT02349139

ASN001-101

P1

Terminated

Prostate Cancer

2017-07-14

2023-02-26

Primary Endpoints|Treatments

Recent News Events

Date

Type

Title